Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Acquisitions & Divestments: 2015-2017

Historic Change in Acquisitions & Divestments for Ocular Therapeutix (OCUL) over the last 2 years, with Sep 2017 value amounting to $3.0 million.

  • Ocular Therapeutix's Change in Acquisitions & Divestments fell 79.57% to $3.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was $54.2 million, marking a year-over-year decrease of 31.98%. This contributed to the annual value of $38.2 million for FY2017, which is 52.65% down from last year.
  • Latest data reveals that Ocular Therapeutix reported Change in Acquisitions & Divestments of $3.0 million as of Q3 2017, which was down 86.78% from $22.7 million recorded in Q2 2017.
  • In the past 5 years, Ocular Therapeutix's Change in Acquisitions & Divestments registered a high of $30.0 million during Q3 2015, and its lowest value of $3.0 million during Q3 2017.
  • For the 3-year period, Ocular Therapeutix's Change in Acquisitions & Divestments averaged around $18.2 million, with its median value being $16.0 million (2016).
  • In the last 5 years, Ocular Therapeutix's Change in Acquisitions & Divestments increased by 6.67% in 2016 and then plummeted by 79.57% in 2017.
  • Over the past 3 years, Ocular Therapeutix's Change in Acquisitions & Divestments (Quarterly) stood at $15.0 million in 2015, then increased by 6.67% to $16.0 million in 2016, then crashed by 79.57% to $3.0 million in 2017.
  • Its Change in Acquisitions & Divestments was $3.0 million in Q3 2017, compared to $22.7 million in Q2 2017 and $12.5 million in Q1 2017.